Market Snapshot: Dow futures slump 400 points as omicron fears ignite fresh selling to kick off Christmas week trade

Daily Trade

U.S. stock-index futures were trading sharply lower Monday morning, following a losing week on Wall Street amid worries about politics, Fed policy and the fast-spreading omicron variant of COVID-19.

How are stock-index futures trading?
  • S&P 500 futures
    ES00,
    -1.32%

    fell 62 points, or 1.3%, to 4,547.50.

  • Dow Jones Industrial Average futures
    YM00,
    -1.21%

    dropped 438 points, or 1.2%, to 34,816.

  • Nasdaq-100 futures
    NQ00,
    -1.48%

    declined 247 points, or 1.5%, to reach 15,540.

On Friday, the Dow
DJIA,
-1.48%

dropped more than 500 points, or 1.5%, with the S&P 500
SPX,
-1.03%

and Nasdaq Composite
COMP,
-0.07%

following it lower. For the week, the Dow lost 1.7%, the S&P 500 dropped 1.9% and the Nasdaq tumbled 3%.

What’s driving the markets?

As omicron worries and related lockdowns in parts of Europe weighed on investors, news that President Joe Biden’s signature $2 trillion spending plan appeared doomed was being greeted with selling.

Sen. Joe Manchin, D-W.Va., said on Sunday that he cannot support it — potentially handing Biden and Democrats a major political loss.

Goldman Sachs downgraded their U.S. growth forecasts for 2022, citing difficulties in getting the spending bill passed.

Last week’s losses came as investors weighed the Federal Reserve’s hawkish pivot, speeding up its reduction of monthly bond purchases and predicting three interest-rate hikes next year.

“With flight to safety being the overriding concern, lower bond yields are questioning the FOMC’s ability to act as hawkish as they signaled last week. Markets are being challenged by a range of uncertainties at a time where thinner trading volumes ahead of the holiday period can exacerbate price swings,” said John Hardy, head of FX strategy at Saxo Bank, in a note to clients.

Need to know: These are the big levels to watch for the S&P 500 and Nasdaq. Expect ‘wild trade,’ if they break, warns this strategist.

Stock futures appeared to pare losses slightly after Moderna
MRNA,
+4.53%

said its COVID-19 booster, when combined with two vaccines, offers 37-fold protection against the omicron variant.

That’s as new COVID-19 cases are growing sharply in many parts of the world, fueled by the rapid spread of that variant. Dr. Anthony Fauci said Sunday that he expects record cases of COVID-19 this winter, and urged people to get vaccinated and get boosters. The Netherlands began a lockdown that will last until mid-January and the U.K. hasn’t ruled out tighter pre-Christmas restrictions.

The World Economic Forum announced that its Davos meeting, which was due to be held in January, will be delayed to summer 2022, due to the spread of COVID-19. It’s the second straight year that the conference has been postponed.

Read: Cathie Wood says stocks have corrected into ‘deep value territory’ and won’t let benchmarks ‘hold our strategies hostage’

Selling of perceived riskier assets extended to oil prices, which fell sharply on concerns of a growing hit to the global economy. Front-month West Texas intermediate crude
CL.1,
-4.15%

fell 4.8% to $67.43 a barrel, while Brent crude
BRN00,
-3.40%
,
the global benchmark, lost 4.1% to $70.48 a barrel.

Wall Street also has a shortened week coming up, with markets closed Friday for the Christmas holiday.

Which companies are in focus?
  • Shares of BP Midstream Partners BPMP surged 13% in premarket trading after energy giant BP said it has entered into a definitive agreement to buy the master limited partnership in an all stock-deal.

  • Novavax shares NVAX rose 10% in premarket after the European Medicines Agency recommended granting Emergency Use Authorization for its COVID-19 vaccine.

  • Moderna
    MRNA,
    +4.53%

    stock rose 7% in premarket trading after the pharmaceutical group said a booster shot of its COVID-19 vaccine provided 37-fold protection against the omicron variant when combined with two vaccine shots.

  • Biogen
    BIIB,
    +0.81%

    shares gained over 2% after the biotechnology company said it would cut the price of its Alzheimer’s drug aduhlem by 50% starting Jan. 1 to about $28,200 a year

  • Bluebird Bio
    BLUE,
    +13.34%

    shares were halted in premarket trading afer the company announced a partial clinical hold for patients under 18 in sickle cell gene therapy program

How are other assets trading?
  • The yield on the 10-year Treasury note
    TMUBMUSD10Y,
    1.398%

    fell about one basis point to 1.391%, according to Dow Jones Market Data. Treasury yields and prices move in opposite directions.

  • The ICE U.S. Dollar Index 
    DXY,
    -0.21%
    ,
     a measure of the currency against a half-dozen other monetary units, was down under 0.1%.

  • Gold futures GC00 for February delivery 
    GCG22,
    -0.42%

    fell 0.4% to $1,797.60 an ounce.

  • The Stoxx Europe 600 Index 
    SXXP,
    -1.45%

     dropped 1.4%, while London’s FTSE 100 index
    UKX,
    -1.11%

    fell 1.1%.

  • In Asia, the Shanghai Composite Index 
    SHCOMP,
    -1.07%

     lost 1%, the Hang Seng Index 
    HSI,
    -1.93%

    fell 1.9% in Hong Kong, China’s CSI 300 
    000300,
    -1.50%

    skidded 1.5% lower and Japan’s Nikkei 225 Index 
    NIK,
    -2.13%

    dropped 2.1%.

Articles You May Like

Here’s why FedEx plans to spin off its freight business
Quantum Computing Revolution: The Gargantuan Opportunity Investors Shouldn’t Ignore
‘She has two financially stable children’: Does it make sense for my wealthy mother, a recent widow, to take out a $100,000 life-insurance policy?
Drone stocks are surging on Wall Street, led by Red Cat Holdings
Wall Street’s fear gauge — the VIX — saw second-biggest spike ever on Wednesday